Literature DB >> 28743160

The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients.

Jack P Silva1, Richard A Gorman1, Nicholas G Berger1, Susan Tsai1, Kathleen K Christians1, Callisia N Clarke1, Harveshp Mogal1, T Clark Gamblin1.   

Abstract

INTRODUCTION: Alpha-fetoprotein (AFP) has a valuable role in postoperative surveillance for hepatocellular carcinoma (HCC) recurrence. The utility of pretreatment or baseline AFP remains controversial. The present study hypothesized that elevated baseline AFP levels are associated with worse overall survival in HCC patients.
METHODS: Adult HCC patients were identified using the National Cancer Database (2004-2013). Patients were stratified according to baseline AFP measurements into the following groups: Negative (<20), Borderline (20-199), Elevated (200-1999), and Highly Elevated (>2000). The primary outcome was overall survival (OS), which was analyzed by log-rank test and graphed using Kaplan-Meier method. Multivariate regression modeling was used to determine hazard ratios (HR) for OS.
RESULTS: Of 41 107 patients identified, 15 809 (33.6%) were Negative. Median overall survival was highest in the Negative group, followed by Borderline, Elevated, and Highly Elevated (28.7 vs 18.9 vs 8.8 vs 3.2 months; P < 0.001). On multivariate analysis, overall survival hazard ratios for the Borderline, Elevated, and Highly Elevated groups were 1.18 (P = 0.267), 1.94 (P < 0.001), and 1.77 (P = 0.007), respectively (reference Negative).
CONCLUSION: Baseline AFP independently predicted overall survival in HCC patients regardless of treatment plan. A baseline AFP value is a simple and effective method to assist in expected survival for HCC patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  alpha-fetoproteins; biomarkers; carcinoma; hepatocellular; prognosis; survival analysis; tumor

Mesh:

Substances:

Year:  2017        PMID: 28743160     DOI: 10.1002/jso.24742

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

1.  Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.

Authors:  Hikmet Akkiz; Brian I Carr; Kendal Yalçın K; Vito Guerra; Sedef Kuran; Engin Altıntaş; Oğuz Üsküdar; Ümit Karaoğullarından; Ayşegül Özakyol; Salih Tokmak; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Tuğsan Ballı; Ali Demir; Burcu Arslan; Figen Doran
Journal:  Oncology       Date:  2017-12-06       Impact factor: 2.935

2.  Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.

Authors:  Lorenza Rimassa; Robin Kate Kelley; Tim Meyer; Baek-Yeol Ryoo; Philippe Merle; Joong-Won Park; Jean-Frederic Blanc; Ho Yeong Lim; Albert Tran; Yi-Wah Chan; Paul McAdam; Evelyn Wang; Ann-Lii Cheng; Anthony B El-Khoueiry; Ghassan K Abou-Alfa
Journal:  Liver Cancer       Date:  2021-12-03       Impact factor: 11.740

3.  Interleukin-6 as a biomarker in patients with hepatobiliary cancers.

Authors:  Rohit Gosain; Sidra Anwar; Austin Miller; Renuka Iyer; Sarbajit Mukherjee
Journal:  J Gastrointest Oncol       Date:  2019-06

4.  Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Rajesh Kaldate; Robin Kate Kelley; Tim Meyer; Lorenza Rimassa; Philippe Merle; Joong-Won Park; Thomas Yau; Stephen L Chan; Jean-Frederic Blanc; Vincent C Tam; Albert Tran; Vincenzo Dadduzio; David W Markby; Ann-Lii Cheng; Anthony B El-Khoueiry; Ghassan K Abou-Alfa
Journal:  Clin Cancer Res       Date:  2020-07-07       Impact factor: 12.531

5.  Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  World J Clin Cases       Date:  2018-06-16       Impact factor: 1.337

6.  A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy.

Authors:  Jingjing Wu; Peng Zhu; Zhanguo Zhang; Bixiang Zhang; Chang Shu; Lin Chen; Renjie Feng; Abdoul Aziz Mba'nbo Koumpa; Ganxun Li; Qianyun Ge
Journal:  Cancer Biol Med       Date:  2018-11       Impact factor: 4.248

7.  The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma.

Authors:  Yu-Liang Huang; Jun-Rong Wu; Min Fang; Hui-Liu Zhao; Zhi-Min Liu; Jian Ye; Ling-Sha Huang; Bo Zhu
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

8.  Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

Review 9.  Targeted agents for second-line treatment of advanced hepatocellular carcinoma.

Authors:  Nicola Personeni; Tiziana Pressiani; Silvia Bozzarelli; Lorenza Rimassa
Journal:  World J Gastrointest Oncol       Date:  2019-10-15

10.  Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer.

Authors:  Dongmei Mai; Yanfen Zheng; Huan Guo; Peirong Ding; Ruihong Bai; Mei Li; Ying Ye; Jialiang Zhang; Xudong Huang; Dingxin Liu; Qiaoqi Sui; Ling Pan; Jiachun Su; Junge Deng; Guandi Wu; Rui Li; Shuang Deng; Yansen Bai; Yanan Ligu; Wen Tan; Chen Wu; Tangchun Wu; Jian Zheng; Dongxin Lin
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.